An interleukin 6 responsive plasma cell signature is associated with disease progression in systemic sclerosis interstitial lung disease

Systemic sclerosis (SSc) interstitial lung disease (ILD) is among the leading causes of SSc-related morbidity and mortality. Tocilizumab (TCZ, anti-IL6RA) has demonstrated a reduced rate of pulmonary function decline in two phase 2/3 trials (faSScinate and focuSSced) in SSc-ILD patients. We performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Guiquan, Ramalingam, Thirumalai R., Heiden, Jason Vander, Gao, Xia, DePianto, Daryle, Morshead, Katrina B., Modrusan, Zora, Ramamoorthi, Nandhini, Wolters, Paul, Lin, Celia, Khanna, Dinesh, Arron, Joseph R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585397/
https://www.ncbi.nlm.nih.gov/pubmed/37867940
http://dx.doi.org/10.1016/j.isci.2023.108133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585397/
https://www.ncbi.nlm.nih.gov/pubmed/37867940
http://dx.doi.org/10.1016/j.isci.2023.108133

Ejemplares similares